Tag Archive > Cardiovascular Risk

ACCORD-Lipidstudie bringt Patienten mit Typ-2-Diabetes und atherogener Dyslipidämie neue Hoffnung, berichtet eine internationale wissenschaftliche Stiftung

Atlanta, Georgia, March 17, 2010 (ots/PRNewswire) – Das kardiovaskuläre Risiko kann bei Typ-2-Diabetikern um zusätzliche 31 Prozent reduziert werden, die eine atherogene Dyslipidämie mit erhöhten Triglyceriden (TG: 204 mg/dl oder 2,3 mmol/l oder höher) und erniedrigten HDL-Cholesterin-Werten (HDL-C: 34 mg/dl oder 0,88 mmol/l oder weniger),. Dies wird dadurch erreicht, bei Kombination von Simvastatin mit Fenofibrat. [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation

Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

CRESTOR(R) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER

Barcelona (ots/PRNewswire) – A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p

Continue reading

, , , , , , , , , , , ,